Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
4.270
-0.210 (-4.69%)
Nov 20, 2024, 4:00 PM EST - Market closed
Alto Neuroscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | 0.21 |
| Gross Profit | - | - | - | 0.21 |
| Selling, General & Admin | 17.54 | 7.52 | 5.5 | 3.9 |
| Research & Development | 45.84 | 30.29 | 23.69 | 8.37 |
| Operating Expenses | 63.38 | 37.81 | 29.19 | 12.27 |
| Operating Income | -63.38 | -37.81 | -29.19 | -12.06 |
| Interest Expense | -1.4 | -1.37 | - | - |
| Interest & Investment Income | 7.45 | 2.35 | 0.11 | 0 |
| Other Non Operating Income (Expenses) | -0.13 | 0.53 | 1.37 | 2.87 |
| Pretax Income | -57.45 | -36.31 | -27.71 | -9.19 |
| Net Income | -57.45 | -36.31 | -27.71 | -9.19 |
| Net Income to Common | -57.45 | -36.31 | -27.71 | -9.19 |
| Shares Outstanding (Basic) | 19 | 4 | 3 | 2 |
| Shares Outstanding (Diluted) | 19 | 4 | 3 | 2 |
| Shares Change (YoY) | 408.92% | 8.27% | 42.78% | - |
| EPS (Basic) | -3.05 | -9.73 | -8.04 | -3.81 |
| EPS (Diluted) | -3.05 | -9.73 | -8.04 | -3.81 |
| Free Cash Flow | -47.85 | -33.92 | -21.13 | -9.94 |
| Free Cash Flow Per Share | -2.54 | -9.09 | -6.13 | -4.12 |
| Gross Margin | - | - | - | 100.00% |
| Operating Margin | - | - | - | -5740.95% |
| Profit Margin | - | - | - | -4374.76% |
| Free Cash Flow Margin | - | - | - | -4734.29% |
| EBITDA | -62.93 | -37.44 | -28.85 | -11.91 |
| D&A For EBITDA | 0.44 | 0.37 | 0.34 | 0.15 |
| EBIT | -63.38 | -37.81 | -29.19 | -12.06 |
Source: S&P Capital IQ. Standard template.
Financial Sources.